LUBT010
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for LUBT010, covering 2026-01-06 to 2026-01-06. Get the full timeline:
Most recent: Clinical Trial Update: Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD [Phase 3]